Skip to Main Content

Advertisement

Skip Nav Destination

CCR Focus Archive 2012


CCR Focus Archive Home


2017  |  2016  |  2015  |  2014  |  2013  |  2012  |  2011  |  2010  |  2009  |  2008  |  2007  |  2006


Oncogenic Metabolism: Cause or Consequence? (October 15, 2012)
Scientific and Regulatory Challenges in the Development of Molecular Diagnostics (March 15, 2012)
Pancreatic Cancer—Applied Science—The Assault Begins (August 15, 2012)
AACR Clinical and Translational Cancer Research Think Tank Reports (February 1, 2012) Genetically InFormed Therapies for Children with Cancer (May 15, 2012) Drug Development: What Experience Has Taught Us (January 1, 2012)

2012 CCR Focus Sections


CCR Focus Cover

Oncogenic Metabolism: Cause or Consequence?
October 15, 2012
Guest Editor: Beverly Teicher, 18 (20) : 5515–5829

Reinventing Cancer Cell Metabolism
Susan E. Bates

Targeting Cancer Metabolism
Beverly A. Teicher, W. Marston Linehan, and Lee J. Helman

c-Myc and Cancer Metabolism
Donald M. Miller, Shelia D. Thomas, Ashraful Islam, David Muench, and Kara Sedoris

Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells
Mayumi Tamada, Makoto Suematsu, and Hideyuki Saya

IDH1 and IDH2 Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives
Hui Yang, Dan Ye, Kun-Liang Guan, and Yue Xiong

Predicting Drug Targets and Biomarkers of Cancer via Genome-Scale Metabolic Modeling
Livnat Jerby and Eytan Ruppin

Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy
Tineke W.H. Meijer, Johannes H.A.M. Kaanders, Paul N. Span, and Johan Bussink

Back to top


CCR Focus Cover

Pancreatic Cancer—Applied Science—The Assault Begins
August 15, 2012
Guest Editors: Manuel Hidalgo and Daniel D. Von Hoff, 18 (16) : 4217–4475

Pancreatic Cancer: Steps in the Right Direction
Susan E. Bates

Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
Manuel Hidalgo and Daniel D. Von Hoff

Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing
Christine A. Iacobuzio-Donahue Victor E. Velculescu, Christopher L. Wolfgang, and Ralph H. Hruban

The Pancreas Cancer Microenvironment
Christine Feig, Aarthi Gopinathan, Albrecht Neesse, Derek S. Chan, Natalie Cook, and David A. Tuveson

Heterogeneity and Targeting of Pancreatic Cancer Stem Cells
Vesselin R. Penchev, Zeshaan A. Rasheed, Anirban Maitra, and William Matsui

Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply
Anne Le, N.V. Rajeshkumar, Anirban Maitra, and Chi V. Dang

Back to top


CCR Focus Cover

Genetically InFormed Therapies for Children with Cancer
May 15, 2012
Guest Editors: Carol J. Thiele and Susan L. Cohn, 18 (10) : 2733–2800

Progress in Pediatric Cancer
Susan E. Bates

Genetically InFormed Therapies — A "GIFT" for Children with Cancer
Carol J. Thiele and Susan L. Cohn

Promising Therapeutic Targets in Neuroblastoma
Katherine K. Matthay, Rani E. George, and Alice L. Yu

The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp

Using Germline Genomics to Individualize Pediatric Cancer Treatments
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

Back to top


CCR Focus Cover

Scientific and Regulatory Challenges in the Development of Molecular Diagnostics
March 15, 2012
Guest Editor: J. Milburn Jessup and Stephen M. Hewitt, 18 (6) : 1513–1562

Molecular Diagnostics: Are We There Yet?
Susan E. Bates

Leveling the Playing Field: Bringing Development of Biomarkers and Molecular Diagnostics up to the Standards for Drug Development
George Poste, David P. Carbone, David R. Parkinson, Jaap Verweij, Stephen M. Hewitt, and J. Milburn Jessup

Impact of Preanalytic Factors in the Design and Application of Integral Biomarkers for Directing Patient Therapy
Stephen M. Hewitt, Sunil S. Badve, and Laurence D. True

Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use
P. Michael Williams, Tracy G. Lively, J. Milburn Jessup, and Barbara A. Conley

Development and Use of Integral Assays in Clinical Trials
Richard L. Schilsky, James H. Doroshow, Michael LeBlanc, and Barbara A. Conley

Lessons Learned from the Investigational Device Exemption (IDE) Review of Children's Oncology Group Trial AAML1031
Soheil Meshinchi, Stephen P. Hunger, Richard Aplenc, Peter C. Adamson, and J. Milburn Jessup

Biomarker Discovery, Development, and Implementation in France: A Report from the French NCI and Cooperative Groups
Fabrice Andre, Frederique Nowak, Monica Arnedos, Ludovic Lacroix, Patrice Viens, and Fabien Calvo

Back to top


 

AACR Clinical and Translational Cancer Research Think Tank Reports
February 1, 2012
Guest Editors: Kenneth C. Anderson and Raymond N. DuBois, 18 (3) : 606–644

A Millennium Goal for Cancer
Susan E. Bates

Overview of the AACR Clinical and Translational Cancer Research Think Tank Meeting
Kenneth C. Anderson and Raymond N. DuBois

Impact of Genomics on Personalized Cancer Medicine
Carlos L. Arteaga and José Baselga

Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics
David R. Parkinson, Bruce E. Johnson, and George W. Sledge

Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing
Raju Kucherlapati

Imaging: Strategies, Controversies, and Opportunities
Ronald Blasberg and David Piwnica-Worms

Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials
Donald A. Berry, Roy S. Herbst, and Eric H. Rubin

Back to top


CCR Focus Cover

Drug Development: What Experience Has Taught Us
January 1, 2012
Guest Editors: Giuseppe Giaccone and Susan E. Bates, 18 (1) : 21–76

On Drug Development, Chance, and the Prepared Mind
Susan E. Bates

Drug Development: Portals of Discovery
Susan E. Bates, Laleh Amiri-Kordestani, and Giuseppe Giaccone

BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcalá and Keith T. Flaherty

The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
Michael Pollak

Inhibitors Targeting Mitosis: Tales of How Great Drugs Against a Promising Target Were Brought Down by a Flawed Rationale
Edina Komlodi-Pasztor, Dan L. Sackett, and Antonio Tito Fojo

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Len Neckers and Paul Workman

Close Modal

or Create an Account

Close Modal
Close Modal